Oberland Biotech GmbH has completed a CHF 2.5 million seed funding round structured as a convertible instrument, marking a new financing step for the Switzerland-based biotechnology and nutrition company.
The round was supported by 999 Family Office Pte. Ltd. Oberland Biotech operates in the trade, sale, and export of nutritional supplements and food products, and also develops projects across the food, nutrition, and biotechnology sectors.
According to the company, the new capital will be directed toward product development, international expansion, recruitment, and marketing and sales growth. A key part of the expansion strategy will focus on building its presence in the United States and Asian markets as it scales its international operations.
The round was supported by 999 Family Office Pte. Ltd. Oberland Biotech operates in the trade, sale, and export of nutritional supplements and food products, and also develops projects across the food, nutrition, and biotechnology sectors.
According to the company, the new capital will be directed toward product development, international expansion, recruitment, and marketing and sales growth. A key part of the expansion strategy will focus on building its presence in the United States and Asian markets as it scales its international operations.